Table 4.
Poisson regression for number of falls and Cox regression for time to first fracture in osteoarthritis versus non-osteoarthritis participants
| Unadjusted HR/RR (95% CI; p Value) |
Multivariable adjusted HR/RR (95% CI; p Value) |
HR/RR, further adjusted for baseline falls (95% CI; p Value) |
HR, further adjusted for incident falls‡ (95% CI; p value) |
|
|---|---|---|---|---|
| Falls* | 1.26 (1.24 to 1.28; p<0.0001) |
1.24 (1.22 to 1.26; p<0.0001) |
1.14 (1.12 to 1.16; p<0.0001) |
-- |
| Overall fracture† | 1.40 (1.32 to 1.48; p<0.0001) |
1.21 (1.13 to 1.30; p<0.0001) |
1.16 (1.08 to 1.25; p<0.0001) |
1.06 (0.98 to 1.15; p=0.128) |
| Hip fracture† | 1.46 (1.17 to 1.81; p<0.0001) |
1.22 (0.94 to 1.59; p=0.131) |
1.19 (0.91 to 1.55; p=0.206) | 1.08 (0.79 to 1.48; p=0.636) |
| Clinical spine fracture† |
1.80 (1.50 to 2.17; p<0.0001) |
1.27 (1.02 to 1.58; p=0.032) |
1.23 (0.99 to 1.54; p=0.061) | 1.23 (0.96 to 1.59; p=0.104) |
| Wrist/forearm fracture† |
1.38 (1.22 to 1.57; p<0.0001) |
1.24 (1.07 to 1.44; p=0.004) |
1.21 (1.04 to 1.40; p=0.014) | 1.07 (0.91 to 1.26; p- 0.424) |
| Upper arm fracture† |
1.38 (1.13 to 1.69; p<0.0001) |
1.21 (0.96 to 1.54; p=0.112) |
1.17 (0.92 to 1.48; p=0.208) | 1.00 (0.77 to 1.30; p=0.995) |
| Lower leg/ankle | 1.34 (1.05 to 1.70; p=0.018) |
1.00 (0.74 to 1.35; p=0.994) |
0.96 (0.71 to 1.30; p=0.790) | 0.89 (0.63 to 1.25; p=0.500) |
Multivariable models for number of falls (Poisson regression) are adjusted for: age, body mass index, current or past hormone replacement therapy, antiosteoporosis medication use, baseline oral corticosteroid use, region of origin (USA/Canada/Australia/Europe), asthma, chronic obstructive pulmonary disease or emphysema, stroke, Parkinson’s disease, cancer, prior fracture, and smoking status.
Multivariable models are adjusted for: age, body mass index, antiosteoporosis medication use, chronic obstructive pulmonary disease or emphysema, Parkinson’s disease, fracture history, parental hip fracture history, baseline oral corticosteroid use, and secondary osteoporosis (as defined by use of aromatase inhibitors, diagnosis of inflammatory bowel disease, type 1 diabetes, and menopause before age 45 years).
Model includes only those women with complete survey follow-up
CI, confidence interval; HR, hazard ratio; RR, rate ratio.